Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NAFLD - Non-Alcoholic Fatty Liver Disease Clear all
Completed Not applicable Interventional

Effects of Alanine in Patients With Nonalcoholic Steatohepatitis

NCT00586885
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
L-alanine
Drug
Lead sponsor
Keith D Lindor, M.D.
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Jul 23, 2026, 2:05 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
Interventions
GSK4532990, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
80
States / cities
Homewood, Alabama • Chandler, Arizona • Mesa, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

NCT05232071
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Interventions
IVA337, Placebo, Empagliflozin
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Homewood, Alabama • Chandler, Arizona • Conway, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

NCT03213145
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
intraconazole, Rifampin, EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 23, 2026, 2:05 PM EDT
Not yet recruiting Phase 1 Interventional

Human Models of Selective Insulin Resistance: Pancreatic Clamp

NCT06558422
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Not applicable Interventional Results available

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

NCT01285362
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Fish Oil Supplementation, Placebo Supplementation
Drug
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT02413372
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Rialto, California • San Diego, California • Indianapolis, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Oral Proglumide for NASH

NCT04152473
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Proglumide
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Jul 23, 2026, 2:05 PM EDT
Completed No phase listed Observational

De Novo Lipogenesis in Severity of NAFLD

NCT03683589
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate, Obesity, Morbid
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
22 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

NCT02913105
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis NASH
Interventions
LMB763, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Culver City, California • Cypress, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NCT04328077
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
31
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

NCT05712265
View directory record Official record
Conditions
Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Interventions
Miricorilant, Fluvoxamine
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional Results available

Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)

NCT04147195
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
LYS006, Tropifexor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Coronado, California • Los Angeles, California • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 23, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional

Intermittent Fasting for NAFLD in Adults

NCT04899102
View directory record Official record
Conditions
Fatty Liver, Intermittent Fasting, Fatty Liver, Nonalcoholic, Non-Alcoholic Fatty Liver Disease, Liver Fat
Interventions
Time-Restricted, Intermittent Fasting
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 23, 2026, 2:05 PM EDT
Active, not recruiting Not applicable Interventional

Hepatic Energy Fluxes in NASH and NAS Patients

NCT03997422
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, NAS, Overweight or Obesity, Weight Loss, Bariatric Surgery Candidate
Interventions
Vertical Sleeve Gastrectomy (VSG)
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 67 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Not yet recruiting Phase 2 Interventional

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

NCT03867487
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
Interventions
Empagliflozin 10 MG, Placebo Oral Tablet
Drug
Lead sponsor
Justin Ryder
Other
Eligibility
12 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Recruiting No phase listed Observational

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

NCT05728697
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
Interventions
Endoscopic ultrasound shear wave elastography
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

NCT05835180
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
Interventions
TVB-2640 - 50 mg
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Not applicable Interventional Results available

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

NCT02290106
View directory record Official record
Conditions
Obesity, Fatty Liver, Nonalcoholic
Interventions
pitavastatin, PLACEBO
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis

NCT04669158
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis, Fibrosis
Interventions
Idebenone, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Redwood City, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease

NCT00815009
View directory record Official record
Conditions
Fatty Liver
Interventions
Mod Fat/Low Processed Carb Diet and Moderate Exercise, Low Fat Diet and Moderate Exercise, Moderate Exercise Only
Behavioral
Lead sponsor
San Antonio Military Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Jul 23, 2026, 2:05 PM EDT
Recruiting Phase 2 Interventional

Digoxin In NASH (CODIN)

NCT06588699
View directory record Official record
Conditions
NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash, MASH With Fibrosis, MASLD, Fatty Liver Disease, Fatty Liver Disease, Nonalcoholic
Interventions
Digoxin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic Syndrome

NCT02358928
View directory record Official record
Conditions
NAFLD, Fatty Liver, Obesity, Metabolic Syndrome
Interventions
Diet Intervention
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
11 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Jul 23, 2026, 2:05 PM EDT